JBM (Healthcare) (HKG:2161) recorded a 53% rise in attributable profit for the six months ended Sept. 30 to HK$95.9 million from HK$62.5 million in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.
Earnings per share were HK$0.1163 in the fiscal first half, up from HK$0.0687 in the corresponding period of fiscal year 2023.
The Chinese medicine distributor's revenue rose by 22% to HK$399 million in the interim period from HK$326.8 million a year prior.
The firm declared an interim dividend of HK$0.055 per share for the half year, payable Jan. 15, 2025, to shareholders of record on Dec. 20, 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。